THE WIRE · № 60875
Curaleaf International Secures Australian First with TGA Registered Liquid Medical Cannabis Inhalation Device and Extends Availability to New Zealand
01 THE MACHINE READ
WHY IT MATTERS.
Regulatory clearance of a cannabis inhalation device expands Curaleaf's addressable market in Australia and New Zealand, but Curaleaf is not in the allowed ticker list and revenue impact is unquantified.
Cannabis device approvals broaden medical access abroad
Sales figures or further country registrations
Small market size limits revenue contribution
FULL DISPATCH
LONDON, Oct. 2, 2026 /PRNewswire/ -- Curaleaf International, part of Curaleaf Holdings, Inc. (TSX: CURA) in partnership with Jupiter Research LLC, today announced that its Que Medical Inhalation Device (QMID) is available in Australia, following the registration by Australia's Therapeutic...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
SAS, NC State Launch AI Think & Do Tank to Advance Health Research2026-10-01 23:01 UTC
New Phase 3 trial: A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy — Amgen2026-10-01 12:00 UTC
New Phase 3 trial: Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer — AstraZeneca2026-10-01 12:00 UTC
New Phase 3 trial: A Phase 3 Study of [177Lu]Ludotadipep for Metastatic Castration-Resistant Prostate Cancer — FutureChem2026-10-01 12:00 UTC
New Phase 3 trial: A Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age — GlaxoSmithKline2026-10-01 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.